Venture Capital and Investment Banking at the intersection of science,
infrastructure, and sovereign strategy.
Bioscience Equity Partners structures, anchors, and closes institutional capital transactions across life sciences and on infrastructure and sovereign mandates of strategic national importance. Antisoma Venture Capital, the firm’s affiliated anchor fund, leads each life sciences round; the GCC and Asia sovereign consortium closes it.
USD 2.1B+
Aggregate Transaction Value
71
Transactions Structured and Closed
72+
Sovereign and Institutional Fund Partners
WHO WE ARE
Built on discipline.
Sustained by relationships.
Bioscience Equity Partners has been operational since 2011, working with a private consortium of sovereign and institutional investors across the GCC and Asia. The firm does not work with every counterparty. It does not respond to unsolicited approaches from parties not yet known to the consortium. Companies and sovereign principals that earn entry into the BEP process engage a structured, gated pathway that institutional capital demands.
Every mandate brought to BEP’s consortium has been reviewed, structured, and prepared to institutional standards before a single fund manager is approached. The firm anchors, syndicates, and closes.
– Bioscience Equity Partners
DIVISIONS
Two divisions.
One institutional standard.
01 — LIFE SCIENCES
Investment Banking, Venture Capital, and Fund Management
The firm’s anchor sector and the exclusive mandate of Antisoma Venture Capital. Bioscience Equity Partners structures, anchors, and executes capital rounds for biotechnology, medical technology, and digital health companies. Antisoma anchors approximately fifty per cent of every round; the remainder is syndicated and closed across the firm’s consortium of sovereign and quasi-sovereign funds. The firm drives the round from mandate to close.
Biotechnology and therapeutics
Medical technology and diagnostics
Digital health and life sciences platforms
Antisoma Venture Capital — affiliated fund, life sciences mandate
02 — INFRASTRUCTURE & SOVEREIGN ADVISORY
Transaction Design, Structuring, and Execution at the Intersection of Capital, Policy, and Industrial Strategy
A dedicated division structuring and executing infrastructure-grade capital transactions for governments, ministries, sovereign funds, and state-owned enterprises. The unit raises and deploys equity, structured finance, and long-duration debt across capital-intensive sectors where industrial capability and national security converge. The division runs each mandate from origination to close.
Energy infrastructure — nuclear and small modular reactors
Agricultural biotechnology and bioindustrial platforms
Defence-adjacent manufacturing and strategic industrial capability
Government and sovereign advisory mandates
MANDATE TO CLOSE
Capital is structured,
anchored, and delivered.
Bioscience Equity Partners runs every mandate from origination to close. Internal review, structuring, sovereign syndication, and execution are managed end-to-end by the firm. Antisoma anchors the round; the consortium closes it.
The firm does not respond to unsolicited approaches from parties not yet known to the consortium.
CAPABILITIES
Integrated capital solutions. Sovereign syndication. Institutional execution.
01
Equity and Debt Structuring
Integrated capital solutions across equity, structured finance, and long-duration debt facilities. Balance-sheet-aligned financing for infrastructure-grade projects and life sciences platforms alike.
02
Sovereign Capital Delivery
Curated syndication across a private consortium of sovereign and quasi-sovereign funds in the GCC and Asia. Antisoma anchors; the consortium closes.
03
Public-Private Structuring
Public-private capital structuring for strategic national assets. Direct engagement with ministries, sovereign funds, and state-owned enterprises across mandate origination, syndication, and close.
Access is earned, not extended.
INSTITUTIONAL ENQUIRIES BY INTRODUCTION ONLY — engagements@bioscienceequity.com